This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Lysergic acid diethylamide (LSD) in anxiety

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Lysergic acid diethylamide (LSD) is a well-known classic psychedelic substance:

  • psychedelics, including LSD and psilocybin, induce profound acute alterations of mind and mystical-type experiences primarily by interacting with the serotonin 5-HT2A receptor
  • the use of LSD in the management of anxiety was investigated in an investigator-initiated 2-centre trial that used a double-blind, placebo-controlled, 2-period, random-order, crossover design with 2 sessions with either oral LSD (200 μg) or placebo per period (1)
    • the primary endpoint was anxiety symptoms 16 weeks after the last treatment session
    • showed that LSD produced long-lasting and notable reductions in anxiety and comorbid depression symptoms up to 16 weeks

Reference:

  1. Holze F, Gasser P, Müller F, Dolder PC, Liechti ME. Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. Biol Psychiatry. 2023 Feb 1;93(3):215-223.

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.